Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversité NAZI BONI

About this trial

Acute respiratory failure (ARF) is a frequent medical emergency, involving high costs for health organizations and patients who often require intensive care and respiratory assistance. According to an international study, 61% of hypoxemic patients in intensive care receive invasive ventilation \[3\]. Invasive mechanical ventilation is often unavailable in low-income countries and non-invasive ventilatory supports such as continuous positive airway pressure (CPAP) and high-flow oxygen therapy (HFO) were very useful during the COVID-19 pandemic. They reduced the rate of intubation and ICU admissions. In addition, CPAP can be used without a ventilator, no electricity is required. So, it could be a support of choice in low-income countries.

Used of Boussignac-type CPAP could potentially reduce the recourse to intubation in patients with acute hypoxemic respiratory failure in a context where access to invasive ventilation remains very limited.

Eligibility criteria

Qualifiers

Acute respiratory distress, defined as dyspnea respiratory rate ≥ 25 cycles/min

Hypoxemia, defined as the need for more 6 liters of oxygen to maintain an oxygen saturation (SpO2) of ≥ 92%. The fraction of inspired oxygen (FiO2) will be estimated using the 3% rule.

Disqualifiers

Pregnant or breastfeeding women

Persons deprived of their liberty

Exacerbation of asthma, chronic obstructive pulmonary disease, or another chronic respiratory disease

Moderate to large amount of unilateral or bilateral undrained pleural effusion

Trial design

Treatments tested in this trial

  • CPAP

Treatment groups

240 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Université NAZI BONI

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Collaborator